New trial alert: Dose escalated radiation therapy for men with high risk prostate cancer

A new trial, sponsored by the Radiation Therapy Oncology Group (RTOG)and the National Cancer Institute (NCI) is looking at the use of hormone therapy (including steroid 17alpha-monooxygenase TAK-700), together with radiation therapy in treating patients with prostate cancer. The primary objective is thus centered on evaluating "the difference in overall survival of patients with clinically localized prostate cancer with unfavourable prognostic features between standard treatment (ADT and radiotherapy) and standard treatment with the addition of 24 months of TAK-700."

To read more about this trial, click here.